Institutional
Tri Locum Partners LP
CIK 0001826434
$712.5M
Reported AUM
17
Positions
Q1 2026
Period
2026-05-18
Filed
The Brief · Tri Locum Partners LP · Q1 2026
AI · grounded in 13F
Tri Locum Partners LP exited its position in DHR for a reduction of $79.4M. The fund established new positions in ISRG for $70.6M, TMO for $65.1M, and VRTX for $57.7M. Other notable activity includes closing positions in BSX and IONS, while increasing its stake in DEXCOM INC by 65.6%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ | JOHNSON & JOHNSON | $232.77 | 2.02% | 53.90% | 55.59% | $101.3M | 14.22% | −188,640 | −31.3% |
| 2 | ISRG | INTUITIVE SURGICAL INC | $422.06 | 0.77% | -24.24% | 27.71% | $70.6M | 9.91% | +153,250 | NEW |
| 3 | TMO | THERMO FISHER SCIENTIFIC INC | $472.80 | -1.91% | 18.07% | -11.30% | $65.1M | 9.13% | +132,413 | NEW |
| 4 | ASNDUSD | ASCENDIS PHARMA A/S | — | — | — | — | $58.4M | 8.20% | −9,683 | −3.7% |
| 5 | VRTX | VERTEX PHARMACEUTICALS INC | $446.83 | 1.15% | -0.81% | 121.66% | $57.7M | 8.10% | +129,314 | NEW |
| 6 | LLY | ELI LILLY & CO | $1131.42 | 0.55% | 48.00% | 387.10% | $56.8M | 7.98% | −1,489 | −2.4% |
| 7 | MDGL | MADRIGAL PHARMACEUTICALS INC | $486.98 | -1.19% | 75.03% | 457.70% | $54.1M | 7.59% | +17,265 | +20.1% |
| 8 | DXCM | DEXCOM INC | $72.86 | 0.37% | -15.93% | -43.47% | $43.8M | 6.15% | +276,558 | +65.6% |
| 9 | UTHR | UNITED THERAPEUTICS CORP DEL | $549.87 | 0.40% | 68.76% | 202.24% | $41.7M | 5.86% | −50,551 | −41.8% |
| 10 | NUVL | NUVALENT INC | $90.95 | -3.27% | 16.57% | 149.66% | $31.6M | 4.44% | +1,135 | +0.4% |
| 11 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $34.19 | -0.70% | 92.40% | 254.30% | $30.8M | 4.32% | −414,857 | −28.9% |
| 12 | JAZZ | JAZZ PHARMACEUTICALS PLC | $238.57 | -0.62% | 114.68% | 40.73% | $30.0M | 4.21% | +158,663 | NEW |
| 13 | ARGX | ARGENX SE | $891.32 | 5.82% | 52.12% | 192.78% | $23.1M | 3.24% | −6,018 | −16.0% |
| 14 | TARS | TARSUS PHARMACEUTICALS INC | $59.28 | -1.76% | 34.97% | 162.65% | $17.7M | 2.49% | +252,588 | NEW |
| 15 | DNTH | DIANTHUS THERAPEUTICS INC | $80.51 | -4.30% | 327.11% | -29.33% | $12.2M | 1.71% | −476,860 | −76.6% |
| 16 | AXSM | AXSOME THERAPEUTICS INC. | $232.32 | 0.36% | 107.60% | 378.12% | $10.5M | 1.47% | −139,511 | −69.2% |
| 17 | DFTX | DEFINIUM THERAPEUTICS INC | $23.55 | -4.23% | 202.31% | -48.69% | $7.0M | 0.98% | +369,588 | NEW |
| 18 | DHR | DANAHER CORPORATION | $184.30 | -1.25% | -5.33% | -28.54% | — | — | −346,875 | EXITED |
| 19 | BSX | BOSTON SCIENTIFIC CORP | $48.55 | -0.61% | -52.44% | 6.47% | — | — | −520,508 | EXITED |
| 20 | IONS | IONIS PHARMACEUTICALS INC | $74.48 | -0.87% | 111.05% | 100.54% | — | — | −557,174 | EXITED |
| 21 | VERA | VERA THERAPEUTICS INC | $32.29 | -3.27% | 42.25% | 79.39% | — | — | −805,689 | EXITED |
Source: SEC EDGAR · accession 0001826434-26-000004. 13F discloses long positions only — shorts, foreign equities, and options are excluded.